INS and type 2 diabetes mellitus: Wright et al.,60 in this retrospective, observational study, conducted an analysis of the Explorys commercial databases to assess the impact of CGM in 1034 poorly controlled T2D adults (baseline HbA1c 10.1%) treated with basal insulin (n = 306) or NIT (n = 728).60 At 6 months following acquisition of the isCGM sensor, investigators observed significant reductions in HbA1c in the basal-insulin group (−1.1%, P < 0.001) and noninsulin treatment group (−1.6%, P < 0.001).